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Open acceAbstract Genomic aberrations of key regulators of the apoptotic pathway have hardly been
identiﬁed in neuroblastoma. We detected high BCL2mRNA and protein levels in the majority
of neuroblastoma tumours by Affymetrix expression proﬁling and Tissue Micro Array anal-
ysis. This BCL2 mRNA expression is strongly elevated compared to normal tissues and other
malignancies. Most neuroblastoma cell lines lack this high BCL2 expression. Only two neuro-
blastoma cell lines (KCNR and SJNB12) show BCL2 expression levels representative for neu-
roblastoma tumours. To validate BCL2 as a therapeutic target in neuroblastoma we employed
lentivirally mediated shRNA. Silencing of BCL2 in KCNR and SJNB12 resulted in massive
apoptosis, while cell lines with low BCL2 expression were insensitive. Identical results were
obtained by treatment of the neuroblastoma cell lines with the small molecule BCL2 inhibitor
ABT263, which is currently being clinically evaluated. Combination assays of ABT263 with
most classical cytostatics showed strong synergistic responses. Subcutaneous xenografts of a
neuroblastoma cell line with high BCL2 expression in NMRI nu/nu mice showed a strong
response to ABT263. These ﬁndings establish BCL2 as a promising drug target in neuroblas-
toma and warrant further evaluation of ABT263 and other BCL2 inhibiting drugs.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. partment of Oncogenomics,
iversity of Amsterdam, Mei-
The Netherlands. Tel.: +31
a.nl (J.J. Molenaar).
ss under the Elsevier OA license. 1. Introduction
BCL2 is an anti-apoptotic member of the BCL2
family proteins.1 When localised at the outer mitochon-
drial membrane it binds BAX and BAK resulting in
Fig. 1. BCL2 expression in neuroblastoma tumours and cell lines. (a) BCL2 RNA expression data in neuroblastoma tumours and cell lines (red),
other tumours (blue) and normal tissue (green) based on Aﬀymetrix proﬁling. In a combined boxdot-plot every dot represents one sample; the
number of tumour samples is given between brackets. The coloured boxes represent the area between the 25th and the 75th percentile with a line in
between indicating the median. (b) Left: correlation between Aﬀymetrix BCL2 RNA expression data (Y-axis) and BCL2 protein expression (3
expression groups are shown on the X-axis) based on a tissue array of the same tumours. Signiﬁcance is indicated by *. Right: example of
immunohistochemistry of a tumour with high BCL2 expression (ITCC0221) and low BCL2 expression (ITCC0119). (c) For all cell lines of the panel
the BCL2 RNA expression level based on Aﬀymetrix proﬁling is represented. Red: >4 average (A), Orange: >2A <4A, Yellow: >0.5A <2A,
Green: <0.5 A. Western blots of BCL2 expression in cell line panel were incubated with BCL2 and actin antibodies. (d) BCL2 RNA expression data
in neuroblastoma tumour cells, adrenal neuroblasts and adrenal cortex. Every dot represents one sample. The line represents the average
expression. Signiﬁcance is indicated by * (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version
of this article).
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release of caspase-activating proteins.1,2 BCL2 was orig-
inally identiﬁed as a partner of t(14;18) translocations
that occur in nearly all cases of follicular lymphoma
and in some diﬀuse large B-cell lymphoma. Also ampli-
ﬁcation of BCL2 is found in these malignancies.3 BCL2
transgenic mice are known to develop follicular lym-
phoma, indicating its oncogenic function.4 Deregulation
of other BCL2 family members is found in several other
tumour types and is correlated with therapy resis-
tance.1,2 BCL2 inhibitors are in phase 1/2 clinical trials
for several malignancies such as chronic lymphocytic
leukaemia, glioblastoma, small cell lung cancer and
malignant melanoma, showing promising results.1,5–7
Neuroblastoma are paediatric tumours that originate
from the embryonal precursor cells of the sympathetic
nervous system. Despite extensive treatment, children
with high stage neuroblastoma have a poor prognosis
with 20–40% overall survival.8–11 Genomic aberrations
in genes directly involved in apoptotic signalling are rare
in neuroblastoma. Deregulation seems to be caused by
epigenetic events.12,13 P53 is mostly intact in primary
neuroblastoma although signalling has shown to be dis-
turbed.10 CASP8 (Caspase 8) is hypermethylated and
thereby inactive in some neuroblastoma resulting in an
inactive extrinsic apoptotic pathway.10 And ﬁnally the
inhibitor of apoptosis gene BIRC5 (Survivin) is highly
expressed in neuroblastoma, which correlates to a poor
prognosis.14–16 None of these signalling proteins is cur-
rently a prime candidate for targeted inhibition. P53
inhibition by Nutlin has shown to be eﬀective in
neuroblastoma but clinical application awaits new
generations of this type of compound.17 Direct inhibi-
tors of BIRC5 signalling are not available, but
YM155, a transcriptional inhibitor of BIRC5 has shown
promising results in vitro and in vivo.18–23 However,
additional targets in the apoptotic pathway for which
clinically applicable compounds are available are
urgently needed.
The role of BCL2 family members in neuroblastoma
has been subject of several studies. BCL2 expression
was reported to be strongly increased in developing sym-
pathetic nervous system and was suggested to regulate
survival during maturation.24–26 Another member of
the BCL2 family, MCL1, has been suggested to mimic
the BCL2 function and to circumvent the eﬀects of
BCL2 inhibition in neuroblastoma. Compounds that
modulate both MCL1 and BCL2 were found to be most
eﬀective in neuroblastoma cell lines and a proﬁle of the
pro-apoptotic members of the BCL2 family proteins
can predict sensitivity of neuroblastoma cell lines to
BCL2 inhibitors.27,28
Several inhibitors of BCL2 are currently in clinical
trials.5,12,13 G3139 is an antisense oligodeoxynucleotide
targeting BCL2 mRNA resulting in RNAse H activa-
tion. ABT263 is a small molecule mimetic of the BH3
domain of the pro-apoptotic BAD protein that iscurrently in clinical trial in chronic lymphatic leukae-
mia.29 ABT263 binds with high aﬃnity to BCL2,
BCLXL and BCLW resulting in inhibition of these pro-
teins, but binds with a much lower aﬃnity to MCL1 and
BCL2A130 This BCL2 small molecule inhibitor has been
studied in the Paediatric Preclinical drug Testing Pro-
gramme (PPTP) and was not found to be eﬀective in ﬁve
neuroblastoma in vivo tumour models.31
In this study we showed that most neuroblastoma
tumours have high BCL2 expression, but most neuro-
blastoma cell lines lack BCL2. Targeted inhibition of
BCL2 by lentiviral shRNA resulted in massive apoptosis
in two neuroblastoma cell lines with high BCL2 expres-
sion, but not in neuroblastoma cell lines with low or
absent expression of BCL2. The small molecule BCL2
inhibitor ABT263 achieved the same results. Combina-
tion assays of ABT263 with most classical cytostatics
showed strong synergistic responses. ABT263 showed
anti-tumour eﬃcacy in a neuroblastoma xenograft
model. Our pre-clinical data package provides a strong
rational for clinical development of ABT263 in neuro-
blastoma patients.2. Methods
2.1. Patient material
The neuroblastic tumour panel used for Aﬀymetrix
microarray analysis contains 88 neuroblastoma samples.
All samples were derived from primary tumours
obtained at diagnosis from patients treated at the Emma
Children’s Hospital in Amsterdam from 1991. Material
was obtained during surgery and immediately frozen in
liquid nitrogen.2.2. Cell lines
All cell lines were grown in Dulbecco Modiﬁed Eagle
Medium (DMEM), supplemented with 10% foetal calf
serum, 10 mM L-glutamine, 10 U/ml penicillin, Non
Essential Amino Acids (1) and 10 lg/ml streptomycin.
Cells were maintained at 37 C under 5% CO2. For pri-
mary references of these cell lines, see Molenaar et al.322.3. Lentiviral shRNA production and transduction
Lentiviral particles were produced in HEK293T cells
by cotransfection of lentiviral vector containing the
short hairpin RNA (shRNA) with lentiviral packaging
plasmids pMD2G, pRRE and pRSV/REV using
FuGene HD. Supernatant of the HET293T cells was
harvested at 48 and 72 h after transfection, which was
puriﬁed by ﬁltration and ultracentrifuging. The concen-
tration was determined by a p24 ELISA.
Cells were plated in a 10% conﬂuence. After 24 h cells
were transduced with lentiviral BCL2 shRNA (Sigma,
3096 F. Lamers et al. / European Journal of Cancer 48 (2012) 3093–3103TRCN0000040069 and TRCN0000040071) in various
concentrations (multiplicity of infection (MOI): 1–3).
SHC-002 shRNA (non-targeting shRNA: CAACAA-
GATGAAGAGCACCAA) was used as a negative con-
trol. 24 h after transduction medium was refreshed and
puromycin was added to determine the eﬃcacy of trans-
duction. Protein was harvested 72 h after transduction
and analysed by Western blot. Nuclei were harvested
48 and 72 h after transfection for FACS (Fluores-
cence-activated cell sorting) analysis.
2.4. Lentiviral over-expression clones
BCL2 and MCL1 cDNA was obtained from a plas-
mid provided by addgene (plasmid 21605 and
8768:3336)33,34 and cloned into pLenti4/TO/V5-Dest
according to manufacturer’s procedures (Invitrogen).
The sequence has been checked using the manufacturer’s
primers (pL4-TO/V5 fwd and pL4-dest rev).
2.5. Compounds
ABT263. (Toronto Research Chemicals) was dis-
solved in DMSO (dimethyl sulfoxide) in a stock concen-
tration of 20 mM from which concentration series were
made in medium from 0.001 to 100 lM. Other com-
pounds used were obtained from Sigma–Aldrich. Stock
solutions were made for vincristin (10 mM in dH2O),
etoposide (50 mM in DMSO), cisplatin (50 mM in
DMF (dimethylformamide)) and doxorubicin (50 mM
in dH2O).
2.6. Mouse model
The animal experiments were performed with permis-
sion and according to the standards of the Dutch com-
mittee for animal research ethics (DEC 101934).
2.5  106 cells of KCNR were injected subcutaneously
in both ﬂanks of NMRI nu/nu mice. Tumours were
allowed to grow to 500 mm3. One of these subcutaneous
tumours was harvested and cut in pieces of 2  2 mm for
subsequent subcutaneous transplantation in both ﬂanks
of the next generation mice. For the experiment we used
two groups of six mice each andwe started treatment four
days after implantation of the tumours. One group was
treated with ABT263 in a concentration of 100 mg/kg/
day (in 100 ll 5% DMSO, 9.5% ethanol, 28.5% polyeth-
ylene glycol, 57% Phosal 50 PG) and the other group
was treated with 100 ll of vehicle only for 21 days orally.
3. Results
3.1. BCL2 is over-expressed in most neuroblastoma
tumours but only sporadic in cell lines
BCL2 family members are up-regulated in many kinds
of cancer.28 They include BCL2, MCL1, BCLXL,
BCLW, BCLB and BFL1 and can be functionallyredundant.1,35 We therefore analysed the expression of
all family members in neuroblastoma tumours using
Aﬀymetrix expression data. BCL2 is the only family
member that shows a strong up-regulation in neuroblas-
toma tumours compared to other cancer types and com-
pared to various normal tissues (Fig. 1a). The other anti-
apoptotic BCL2 family members were equally or lower
expressed in neuroblastoma compared to other tumours
and normal tissues (Suppl. Figs. 1/2). To study the corre-
lation between BCL2 mRNA and protein expression in
neuroblastoma, we performed tissue array analysis of
42 neuroblastoma tumours with three core biopsies per
sample. All 42 tumours had cytoplasmic staining for
BCL2 but a clear variation was visible (Suppl. Fig. 3).
All tumours were scored and categorised into three
groups. Low BCL2 protein expression was scored in six
tumours whereas 14 tumours displayed intermediate
and 22 tumours high BCL2 protein levels. Tumours with
a high BCL2 mRNA expression showed signiﬁcantly
higher BCL2 protein levels (Fig. 1b), indicating that
BCL2 mRNA levels are representative for BCL2 protein
levels in neuroblastoma tumours.
Neuroblastoma cell lines have a much lower BCL2
mRNA expression compared to neuroblastoma tumours
(Fig. 1a). KCNR and SJNB12 were the only two cell
lines with BCL2 mRNA expression levels comparable
to tumours. Western blot analysis of all cell lines in
our panel revealed that, like in tumours, high BCL2
mRNA levels correspond with high BCL2 protein levels
(Fig. 1c). We conclude that only a few neuroblastoma
cell lines are suited to study the eﬀects of BCL2 inhibi-
tion in neuroblastoma.
To investigate whether high BCL2 expression levels
are related to genomic defects in neuroblastoma, we ana-
lysed the BCL2 locus on chromosome 18 in array CGH
data of our neuroblastoma series. Whole chromosome
18 gain was detected in 15 out of 88 neuroblastoma
tumours, but BCL2 mRNA levels did not correlate to
chr.18 gain (data not shown), suggesting that BCL2
expression is transcriptionally regulated. To analyse
whether high BCL2 expression is a property of the sym-
patho-adrenal lineage from which neuroblastoma are
derived,we compared theBCL2mRNAexpressionof nor-
mal adrenal neuroblasts and tumours in a published series
of de Preter et al.36 and found no signiﬁcant diﬀerences
(Fig. 1d). This is in agreement with earlier immunohisto-
chemical analyses26, and suggests that high BCL2 expres-
sion is a characteristic of the sympathetic adrenal lineage.
3.2. BCL2 silencing results in apoptosis in a subset of
neuroblastoma cell lines
We selected ﬁve neuroblastoma cell lines with various
BCL2 expression levels, of which KCNR and
SJNB12 have high expression, LAN5 and SKNBE have
intermediate expression and SKNAS has low BCL2
expression. In all cell lines BCL2 was silenced using two
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sequence. Western blot analysis showed a >80% decrease
of BCL2 protein expression 72 h after transduction in all
cell lines with BCL2 expression (Fig. 2a). BCL2 silencing
resulted in cell death 72 h after transduction in the cell
lines with high or intermediateBCL2 expression as shown
by PARP (Poly ADP ribose polymerase) cleavage.
SKNAS has no BCL2 expression and did not show
induction of PARP cleavage after treatment with the
BCL2-speciﬁc shRNA vectors (Fig. 2a). The diﬀerences
in phenotypic eﬀect after BCL2 silencing were conﬁrmed
using light microscopy (Fig. 2b) andMTT assays (3-(4,5-
demethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assays) (Fig. 2c). Both assays showed a strong decrease
of cell viability after silencing BCL2 in cell lines with high
expression of BCL2 while SKNAS was completely insen-
sitive. These ﬁndings suggest thatBCL2 is a potential tar-
get for therapy in neuroblastoma tumours with moderate
to high expression of BCL2.
3.3. ABT263 induces apoptosis in NB cell lines with high
expression of BCL2
The strong phenotypes induced by shRNA-mediated
BCL2 inhibition urged us to test whether these results
can also be achieved by a clinically applicable com-
pound. ABT263 is a small molecule BCL2 inhibitor cur-
rently in clinical testing. We treated the same ﬁve
neuroblastoma cell lines with ABT263. The results were
strikingly similar to the phenotypes after BCL2 shRNA
treatment. The four cell lines with high or intermediate
BCL2 expression showed apoptotic cell death as indi-
cated by Parp cleavage (Fig. 3a) and an increase in
sub G1 fraction on FACS analysis (Fig. 3b, Table 1),
whereas SKNAS was completely insensitive for the com-
pound at lM concentrations and did not show induc-
tion of apoptosis (Fig. 3a–b). The concentration of
ABT263 required for 50% cell survival (IC50) was deter-
mined for all cell lines in our panel using MTT assays.
The IC50 varied from 0.1 lM in KCNR to >100 lM
in SKNAS (Fig. 3c) and showed an inverse correlation
to the BCL2 RNA expression (Fig. 3d).
These ﬁndings suggest that targeted inhibition of
BCL2 by ABT263 leads to a similar response as targeted
knock down of the BCL2 mRNA. To further test the
BCL2-inhibitory eﬀect of ABT263, we performed a cell
fractionation assay of neuroblastoma cells treated with
ABT263.Western blot analysis showed at 24 h after treat-
ment a strong transient increase of cytoplasmatic levels of
Cytochrome C, which conﬁrms mitochondrial release of
Cytochrome C as a result of BCL2 inhibition (Fig. 3e).3.4. ABT263 inhibits tumour growth in a neuroblastoma
mouse model
The in vitro results of ABT263 urged us to test the
compound in a neuroblastoma mouse model. We usedserial transplants in NMRI nu/nu mice of xenografts
of the human neuroblastoma cell line KCNR. Mice were
treated orally with 100 mg/kg/day ABT263 for 3 weeks.
After treatment, the mice were followed until they had
to be terminated due to tumour volume. The ABT263-
treated mice showed a strong delay in tumour growth
and had a reduced tumour take. ABT263 induced a
delay of 29 days on average compared to the DMSO-
treated control mice (Fig. 4a). In the ABT263 treated
mice ﬁve tumours developed out of 12 tumours that
were implanted, whereas in the DMSO treated group
nine out of 12 implants formed tumours. We conclude
that ABT263 also in vivo shows a strong inhibitory eﬀect
on xenografts of a human neuroblastoma cell line with
high BCL2 expression.3.5. Synergy between ABT263 and regular cytostatics
ABT263 potentiates an apoptotic response, suggesting
that synergistic eﬀects in combination with apoptosis
inducing compounds might occur. In addition solid
knowledge of combination treatment with classical cyto-
statics is a requisite for further clinical implementation of
ABT263. We analysed this in MTT synergy assays with
the key compounds used in neuroblastoma treatment
according to the DCOGNBL 2007 trial protocol. Doxo-
rubicin, vincristin and etoposide showed strong synergis-
tic responses with ABT263 in the two neuroblastoma cell
lines SJNB12 and KCNR, which both have a high BCL2
expression (Table 2). ABT263 also showed synergy with
cisplatin in SJNB12, but surprisingly an antagonistic
eﬀect with cisplatin in KCNR. As expected, no enhance-
ment between ABT263 and the other compounds was
observed in neuroblastoma cell line SKNAS, which lacks
BCL2 expression. Also exponentially growing human
ﬁbroblasts (F2112) did not show synergy (Table 2), which
indicates that the synergy is indeed BCL2 dependent and
tumour speciﬁc. The dose eﬀect curve of SJNB12 treated
with a concentration series of doxorubicin combined with
a ﬁxed concentration ofABT263 is represented in Fig. 4b.
The isobologram of the combination of both compounds
with various concentrations is shown in Fig. 4c. The
Combination Index, which represents the degree of syn-
ergism of all drug combinations, is shown in Table 2
for all cell lines tested. In this table the combination index
at a fraction aﬀected of 0.5 is shown (concentration com-
bination of compounds with 50% cell survival). However
synergy was found at a large range of concentration com-
binations. These ﬁndings potentiate ABT263 for imple-
mentation in neuroblastoma treatment protocols and
warrant further in vivo analysis.4. Discussion
Neuroblastoma tumours have a very high BCL2
RNA and protein expression, whereas the majority of
Fig. 2. Knockdown of BCL2 with lentiviral shRNA. (a) Protein lysates were made 72 h after transduction of the cells of Fig. 2b including the
ﬂoating cells. Western blot was performed and incubated with BCL2, PARP and actin antibodies. (b) Twenty-four hours after plating, cells were
transduced with two diﬀerent lentiviral BCL2 shRNAs. Pictures of the cells were made 72 h after transduction with a 100 magnitude. (c) Twenty-
four hours after plating, cells were transduced with two diﬀerent lentiviral BCL2 shRNAs. MTT assay was performed 7–10 days after transduction.
Cell viability is represented on the Y-axis and the multiplicity of infection (MOI) is represented on the X-axis.
3098 F. Lamers et al. / European Journal of Cancer 48 (2012) 3093–3103neuroblastoma cell lines have not. Two cell lines
(SJNB12 and KCNR) show a BCL2 expression that iscomparable to the in vivo expression. Speciﬁc knock-
down of BCL2 with lentiviral shRNA resulted in the
Fig. 3. ABT263 in cell line panel. (a) Twenty-four hours after plating, cells were treated with an ABT263 concentration series. Protein lysates were
made including the ﬂoating cells. Western blot was performed and incubated with PARP and actin antibodies. (b) Cell lines of the panel were
treated with a concentration series of ABT263 24 h after plating. Seventy-two hours after treatment whole cells, including the ﬂoating cells were
ﬁxed and stained with propidium Iodide for FACS analysis. The Y-axes of the graphs represent the number of events and the X-axes represent the
size of the particles detected. Apoptosis is shown by the sub G1 fraction. (c) Cell viability curves of all cell lines of the panel after treatment with
ABT263 as determined by an MTT-assay. Cell viability is represented on the Y-axis and the ABT263 concentration in lM is represented on the X-
axis. (d) IC50 values of the cell lines tested for ABT263 that were calculated from the data in Fig. 3c are represented by the red bars. BCL2 RNA
expression of these cell lines is shown by the blue bars. (e) Cell fractionation assay performed on SJNB12 cells treated with ABT263. Protein lysates
were harvested 24 h after treatment for Western blot analysis. Blots were incubated with Cytochrome C, BCL2, and a-tubulin antibodies (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article).
F. Lamers et al. / European Journal of Cancer 48 (2012) 3093–3103 3099
Table 1
Apoptosis after ABT263 treatment in neuroblastoma cells.
ABT263 (lM) Sub-G1 fraction (%)
KCNR SJNB12 LAN5 SKNBE SKNAS
0 14 16.1 4.3 10.2 2.2
0.008 19.7 14 * * *
0.04 19.1 18 * * *
0.2 31.7 28.6 30.5 * *
1 41.2 32.1 40.7 14.5 2.6
5 55 37.6 42.5 19.7 3.7
10 * * 36.2 22.5 3.3
15 * * 40 22.5 4.1
20 * * * 28.9 5.5
Apoptotic fraction after treatment with ABT263 in cell line panel.
Percentage of the subG1 fraction as determined by FACS analysis.
3100 F. Lamers et al. / European Journal of Cancer 48 (2012) 3093–3103most abundant apoptotic response in these cell lines as
shown by MTT assay and PARP cleavage. ABT263Fig. 4. ABT263 in a KCNR xenograft model and synergy assays of AB
volume in mm3; the X-axis represents time in days after start of the treatmen
indicates the start of treatment and arrow 2 the end of the treatment. The
DMSO; the dashed line represents the average tumour volume of mice trea
control group because of large tumours. (b) The dose-eﬀect curve of doxor
Isobologram; the X-axis represents the concentration for ABT263 with a do
for doxorubicin, with a dot that represents its IC50 level. The line repr
combined. X = actual concentrations of both drugs where an IC50 level wsynergistically sensitised neuroblastoma cell lines for
most cytotoxic compounds. Treatment of neuroblas-
toma xenografts in a mouse model with ABT263
resulted in reduced and delayed tumour growth. We
conclude that BCL2 is a potential new drug target in
neuroblastoma and that further validation of the
BCL2 inhibitor ABT263 in vivo and subsequently in
patients is warranted.
Lestini et al.28 analysed BCL2 and MCL1 protein
expression on tissue arrays of neuroblastoma. Both pro-
teins were expressed in the majority of neuroblastoma.
Here we extend these observations by establishing that
BCL2 mRNA expression is much higher in neuroblas-
toma than in most other tumour types and normal tis-
sues. In addition, we show that BCL2 mRNA levels
correlate very well with BCL2 protein levels as estab-
lished by tissue arrays of tumours and Western blotT263 with doxorubicin in SJNB12. (a) The Y-axis represents tumour
t; * indicates the time point that tumour pieces were implanted; arrow 1
solid line represents the average tumour volume of mice treated with
ted with ABT263. From day 61 we had to terminate some mice in the
ubicin without ABT263 (dashed line) and with ABT263 (solid line). (c)
t that represents its IC50 level. The Y-axis represents the concentration
esents the expected curve for IC50 levels when both compounds are
as measured.
Table 2
Synergy between ABT263 and regular cytostatics in neuroblastoma cells.
KCNR SJNB12 SKNAS F2112
Doxorubicin ++++ (0.14) ++++ (0.19) +/– +/–
Cisplatin – – – – – (>10) +++ (0.58) +/– +/–
Vincristine +++ (0.51) +++++ (<0.1) +/– +/–
Etoposide ++++ (0.21) +++++ (<0.1) +/– +/–
Combination Indexes for each cell line treated with ABT263 combined with each drug indicated are presented in this table. The degree of synergism
is presented by + or . +++++: very strong synergism; ++++: strong synergism; +++: synergism;     –: very strong antagonism. +/: no
enhancement. Since SKNAS and F2112 were resistant to ABT263, an IC50 value for this compound was not reached. Therefore a combination
index cannot be determined.
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NA-mediated BCL2 silencing in neuroblastoma cell
lines, including SKNAS. In contrast to our SKNAS cells,
their SKNAS cells showed BCL2 expression and knock-
down, but just like our cells did not show an apoptotic
response.
Several other authors have reported high sensitivity
for BCL2 inhibitors in cell systems with high BCL2
expression. BIM could mediate this process through
release from BCL2 and subsequent activation of BAX.
BIM is evidently expressed in neuroblastoma cell lines
and tumours (data available through the R2 web appli-
cation). MCL1 or BFL1 (A1) over-expression can con-
fer this phenotype. MCL1 mRNA is readily detectable
by Aﬀymetrix micro-arrays but the expression levels
are much lower compared to other tumours. The
mRNA and protein both are known to have a fast turn-
over so we presume that neuroblastoma tumours should
be considered to have a relatively low expression of
MCL1. Our ﬁndings are then in agreement with the
observations that BCL2 speciﬁc BH3 mimics are eﬀec-
tive in cells with BCL2 expression in the presence of
BIM with low MCL1 and BFL1 (A1) levels.37,38
ABT263 has previously been tested in a cell line panel
by the Paediatric Preclinical Testing Programme and rel-
atively high IC50 values were found for the neuroblas-
toma cell lines tested.31 BCL2 expression has not been
analysed in these lines, but here we show that most neu-
roblastoma cell lines lack BCL2 expression, which might
explain the weak responses to ABT263. The same holds
for the neuroblastoma xenografts tested for ABT263
sensitivity as reported in the same paper. Also they were
found to be relatively poor responders.
Essentially, our analyses showed that while neuro-
blastoma tumours have very high BCL2 expression,
most neuroblastoma cell lines have low BCL2 expres-
sion. Selection of high BCL2 expressing cell lines for
in vitro and in vivo testing of BCL2 inhibitory small mol-
ecules is therefore essential. The good responses in vitro
and in vivo to ABT263 of neuroblastoma cell lines with
high BCL2 expression suggest that BCL2 might be a
good target for therapy in neuroblastoma. Moreover,
since the BCL2 expression in the selected cell lines is
comparable to the BCL2 levels in most tumours, wehypothesise that most neuroblastoma tumours will be
sensitive for ABT263.
Synergy of BCL2 inhibitors with etoposide or vincris-
tine has previously been shown in other tumour
types.39,40 We also found ABT263 to work synergisti-
cally with all of the currently used cytostatics in neuro-
blastoma treatment with the exception of cisplatin in
SJNB12. The reason for this exception is unclear. For
all other combinations, synergy could be explained by
the working mechanisms of these compounds, which
are all known to mediate DNA damage or microtubule
destabilisation. Cisplatin crosslinks DNA resulting in
activation of DNA repair mechanisms and if that proves
impossible it activates apoptosis. Doxorubicin is an
inhibitor of reverse transcriptase and RNA polymerase,
vincristin disrupts microtubules and etoposide blocks
the cell cycle by inhibiting topoisomerase II.41 All these
mechanisms activate the mitochondrial apoptotic path-
way.42 This apoptotic route requires the release of Cyto-
chrome C from the mitochondria, which is inhibited by
BCL2.2 Over-expression of BCL2 therefore suppresses
apoptosis and cells can be re-sensitised to these com-
pounds by ABT263.
Combination treatment of ABT263 and currently
used cytostatics might in addition increase the speciﬁcity
of the anti-tumour treatment, as we show that BCL2 is
highly expressed in neuroblastoma but not in normal tis-
sues. ABT263 is therefore a promising candidate for fur-
ther in vitro testing and implementation in current
treatment protocols of neuroblastoma patients.
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